Strides Pharma Science has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of Strides Alathur, a wholly owned subsidiary of the Company, at Alathur, Chennai during the week of April 1, 2024 to April 5, 2024. The inspection closed with two observations. Company will respond to these observations comprehensively to FDA within the stipulated time. They will keep the stock exchanges informed if there is any further update in this matter.
The above information is a part of company’s filings submitted to BSE.
